Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis

This was designed to assess the outcomes of side branch (SB) stenosis after implantation of three drug-eluting stents (DES). From 2,645 patients in the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) T...

Full description

Bibliographic Details
Main Authors:	Lee, Bong-Ki, Kim, Young-Hak, Park, Duk-Woo, Yun, Sung-Cheol, Ahn, Jung-Min, Song, Hae Geun, Lee, Jong-Young, Kim, Won-Jang, Kang, Soo-Jin, Lee, Seung-Whan, Lee, Cheol Whan, Lee, Jae-Hwan, Seong, In-Whan, Park, Seong-Wook, Park, Seung-Jung
Format:	Online
Language:	English
Published:	The Korean Academy of Medical Sciences 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524429/

id	pubmed-3524429
recordtype	oai_dc
spelling	pubmed-35244292012-12-19 Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis Lee, Bong-Ki Kim, Young-Hak Park, Duk-Woo Yun, Sung-Cheol Ahn, Jung-Min Song, Hae Geun Lee, Jong-Young Kim, Won-Jang Kang, Soo-Jin Lee, Seung-Whan Lee, Cheol Whan Lee, Jae-Hwan Seong, In-Whan Park, Seong-Wook Park, Seung-Jung Original Article This was designed to assess the outcomes of side branch (SB) stenosis after implantation of three drug-eluting stents (DES). From 2,645 patients in the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Trial, 788 patients had 923 bifurcation lesions with SB ≥ 1.5 mm were included. SB was treated in 150 lesions, including 35 (3.8%) receiving SB stenting. Of untreated SB with baseline stenosis < 50%, the incidences of periprocedural SB compromise was similar in the zotarolimus (15.8%), sirolimus (17.2%), and paclitaxel (16.6%) stent groups (P = 0.92). At follow-up angiography, delayed SB compromise occurred in 13.9%, 3.2%, and 9.4% (P = 0.010) of these groups. When classified into four groups (< 50%, 50%-70%, 70%-99%, and 100%), 9.0% of untreated SB were worsened, whereas improvement and stationary were observed in 9.6% and 81.4%. In a multivariable logistic regression model, main branch (MB) stenosis at follow-up (%) was the only independent predictor of SB stenosis worsening (odds ratio, 1.03; 95% confidence interval, 1.01-1.04; P < 0.001). After MB stenting in bifurcation lesions, a minority of SB appears to worsen. DES with strong anti-restenotic efficacy may help maintain SB patency. The Korean Academy of Medical Sciences 2012-12 2012-12-07 /pmc/articles/PMC3524429/ /pubmed/23255849 http://dx.doi.org/10.3346/jkms.2012.27.12.1499 Text en © 2012 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Lee, Bong-Ki Kim, Young-Hak Park, Duk-Woo Yun, Sung-Cheol Ahn, Jung-Min Song, Hae Geun Lee, Jong-Young Kim, Won-Jang Kang, Soo-Jin Lee, Seung-Whan Lee, Cheol Whan Lee, Jae-Hwan Seong, In-Whan Park, Seong-Wook Park, Seung-Jung
spellingShingle	Lee, Bong-Ki Kim, Young-Hak Park, Duk-Woo Yun, Sung-Cheol Ahn, Jung-Min Song, Hae Geun Lee, Jong-Young Kim, Won-Jang Kang, Soo-Jin Lee, Seung-Whan Lee, Cheol Whan Lee, Jae-Hwan Seong, In-Whan Park, Seong-Wook Park, Seung-Jung Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
author_facet	Lee, Bong-Ki Kim, Young-Hak Park, Duk-Woo Yun, Sung-Cheol Ahn, Jung-Min Song, Hae Geun Lee, Jong-Young Kim, Won-Jang Kang, Soo-Jin Lee, Seung-Whan Lee, Cheol Whan Lee, Jae-Hwan Seong, In-Whan Park, Seong-Wook Park, Seung-Jung
author_sort	Lee, Bong-Ki
title	Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
title_short	Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
title_full	Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
title_fullStr	Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
title_full_unstemmed	Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis
title_sort	acute and long-term angiographic outcomes of side branch stenosis after randomized treatment of zotarolimus-, sirolimus-, and paclitaxel-eluting stent for coronary artery stenosis
description	This was designed to assess the outcomes of side branch (SB) stenosis after implantation of three drug-eluting stents (DES). From 2,645 patients in the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Trial, 788 patients had 923 bifurcation lesions with SB ≥ 1.5 mm were included. SB was treated in 150 lesions, including 35 (3.8%) receiving SB stenting. Of untreated SB with baseline stenosis < 50%, the incidences of periprocedural SB compromise was similar in the zotarolimus (15.8%), sirolimus (17.2%), and paclitaxel (16.6%) stent groups (P = 0.92). At follow-up angiography, delayed SB compromise occurred in 13.9%, 3.2%, and 9.4% (P = 0.010) of these groups. When classified into four groups (< 50%, 50%-70%, 70%-99%, and 100%), 9.0% of untreated SB were worsened, whereas improvement and stationary were observed in 9.6% and 81.4%. In a multivariable logistic regression model, main branch (MB) stenosis at follow-up (%) was the only independent predictor of SB stenosis worsening (odds ratio, 1.03; 95% confidence interval, 1.01-1.04; P < 0.001). After MB stenting in bifurcation lesions, a minority of SB appears to worsen. DES with strong anti-restenotic efficacy may help maintain SB patency.
publisher	The Korean Academy of Medical Sciences
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524429/
_version_	1611941081551732736

Acute and Long-Term Angiographic Outcomes of Side Branch Stenosis after Randomized Treatment of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stent for Coronary Artery Stenosis

Similar Items